None listed
Conditions
Brief summary
The purpose of this study is to examine the safety of completing a stem cell transplant of your own cells in the outpatient setting. Who is it for? You may be eligible for this study if you are aged 18 -75 and are undergoing a stem cell transplant with your own cells at Nepean Hospital. Study Details Participants will choose between two locations for their transplant, inpatient or outpatient. Inpatient participants will receive all pre-transplant, transplant and post transplant care in hospital. Inpatient participants will be discharged when they are well enough. Outpatient participants will come to the centre for their pre-transplant chemotherapy, transplant and post transplant care but be able to stay at home between visits until they become unwell or require extra care unable to be provided at home. The outpatient participants will also take oral antibiotics after the transplant. As part of this study, participants and their carers will complete questionnaires and consent to study staff reviewing their medical records. It is hoped this research will show that stem cell transplant can be performed in an outpatient setting, which may improve quality of life.
Interventions
Standard pre-transplant chemotherapy with Melphalan will be provided by an outpatient cancer nurse the day prior to the autologous transplant in the cancer centre.
Autologous stem cell transplant will be provided by an outpatient cancer nurse in the cancer centre the day after the chemotherapy.
Post transplant supportive care in the outpatient setting will occur at the cancer centre and in the patient's home; patient's will complete a daily diary to assist with monitoring their condition (the di
Standard pre-transplant chemotherapy with Melphalan will be provided by an outpatient cancer nurse the day prior to the autologous transplant in the cancer centre. Autologous stem cell transplant will be provided by an outpatient cancer nurse in the cancer centre the day after the chemotherapy. Post transplant supportive care in the outpatient setting will occur at the cancer centre and in the patient's home; patient's will complete a daily diary to assist with monitoring their condition (the diary records fluid input and output, temperature recordings, medication and food intake), patient's will visit the cancer centre every second day from the transplant onwards (not including weekends) and be phoned by centre staff on alternate days, bloods will be taken and checked on average every 2 days, intravenous fluids/blood products/medication will be provided on visits to the cancer centre as required. No health professional will visit the patient's home. All this will occur for a minimum of 12 days post transplant, and a maximum of 28 days post transplant. A comparison will be made to pre-transplant chemotherapy, autologous stem cell transplant, and post transplant supportive care in the inpatient setting at Nepean Hospital. This study will span 7 weeks for each participant.
Sponsors
Nepean Blue Mountains Local Health District
Study design
Allocation
Non-randomised trial
Intervention model
Parallel
Primary purpose
Treatment
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
diagnosis of multiple myeloma to be treated with Melphalan pre-transplant ECOG 0,1,or 2 Fit for autologous stem cell transplant at Nepean Hospital Participant willing to participate in the trial carer available transport and driver available complies with cohort distance requirements
Exclusion criteria
Not fit for Autologous stem cell transplant Unwilling to participate
Outcome results
None listed